245 related articles for article (PubMed ID: 26942101)
1. Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Ramos P; Karnezis AN; Hendricks WP; Wang Y; Tembe W; Zismann VL; Legendre C; Liang WS; Russell ML; Craig DW; Farley JH; Monk BJ; Anthony SP; Sekulic A; Cunliffe HE; Huntsman DG; Trent JM
Rare Dis; 2014; 2(1):e967148. PubMed ID: 26942101
[TBL] [Abstract][Full Text] [Related]
2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
Lin DI; Chudnovsky Y; Duggan B; Zajchowski D; Greenbowe J; Ross JS; Gay LM; Ali SM; Elvin JA
Gynecol Oncol; 2017 Dec; 147(3):626-633. PubMed ID: 29102090
[TBL] [Abstract][Full Text] [Related]
4. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.
Clarke BA; Witkowski L; Ton Nu TN; Shaw PA; Gilks CB; Huntsman D; Karnezis AN; Sebire N; Lamovec J; Roth LM; Stewart CJ; Hasselblatt M; Foulkes WD; McCluggage WG
Histopathology; 2016 Nov; 69(5):727-738. PubMed ID: 27100627
[TBL] [Abstract][Full Text] [Related]
5. Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.
Orlando KA; Douglas AK; Abudu A; Wang Y; Tessier-Cloutier B; Su W; Peters A; Sherman LS; Moore R; Nguyen V; Negri GL; Colborne S; Morin GB; Kommoss F; Lang JD; Hendricks WP; Raupach EA; Pirrotte P; Huntsman DG; Trent JM; Parker JS; Raab JR; Weissman BE
Elife; 2020 Dec; 9():. PubMed ID: 33355532
[TBL] [Abstract][Full Text] [Related]
6. Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
Fahiminiya S; Witkowski L; Nadaf J; Carrot-Zhang J; Goudie C; Hasselblatt M; Johann P; Kool M; Lee RS; Gayden T; Roberts CW; Biegel JA; Jabado N; Majewski J; Foulkes WD
Oncotarget; 2016 Jan; 7(2):1732-40. PubMed ID: 26646792
[TBL] [Abstract][Full Text] [Related]
7. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
8. Biallelic somatic SMARCA4 mutations in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Bailey S; Murray MJ; Witkowski L; Hook E; Hasselblatt M; Crawford R; Foulkes WD; Tischkowitz M; Nicholson JC
Pediatr Blood Cancer; 2015 Apr; 62(4):728-30. PubMed ID: 25307865
[TBL] [Abstract][Full Text] [Related]
9. Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) beyond
Auguste A; Blanc-Durand F; Deloger M; Le Formal A; Bareja R; Wilkes DC; Richon C; Brunn B; Caron O; Devouassoux-Shisheboran M; Gouy S; Morice P; Bentivegna E; Sboner A; Elemento O; Rubin MA; Pautier P; Genestie C; Cyrta J; Leary A
Cells; 2020 Jun; 9(6):. PubMed ID: 32575483
[TBL] [Abstract][Full Text] [Related]
10. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
[TBL] [Abstract][Full Text] [Related]
11. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
Ramos P; Karnezis AN; Craig DW; Sekulic A; Russell ML; Hendricks WP; Corneveaux JJ; Barrett MT; Shumansky K; Yang Y; Shah SP; Prentice LM; Marra MA; Kiefer J; Zismann VL; McEachron TA; Salhia B; Prat J; D'Angelo E; Clarke BA; Pressey JG; Farley JH; Anthony SP; Roden RB; Cunliffe HE; Huntsman DG; Trent JM
Nat Genet; 2014 May; 46(5):427-9. PubMed ID: 24658001
[TBL] [Abstract][Full Text] [Related]
12. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
[TBL] [Abstract][Full Text] [Related]
14. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
15. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD
Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340
[TBL] [Abstract][Full Text] [Related]
16. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
Jelinic P; Mueller JJ; Olvera N; Dao F; Scott SN; Shah R; Gao J; Schultz N; Gonen M; Soslow RA; Berger MF; Levine DA
Nat Genet; 2014 May; 46(5):424-6. PubMed ID: 24658004
[TBL] [Abstract][Full Text] [Related]
17. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
18. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
Wang L; Tan C; Tu X; Zhang Y; Li X; Chang B
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
